Key facts
- It has raised $20.0M; the latest was Early Stage VC ($20.0M) in Nov 2025.
- Notable investors include Versant Ventures.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Dayra Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Dayra Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dayra Therapeutics
Developer of oral macrocyclic peptide therapeutics designed to treat a range of serious human diseases. The company combines its proprietary macrocycle discovery with computational design and modeling to create novel macrocyclic peptides that selectively target disease-relevant proteins, enabling global pharmaceutical and biotechnology companies to expand treatment options and improve patient outcomes.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Website
- dayratx.com/
- Ownership
- Privately Held (backing)
Dayra Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dayra Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dayra Therapeutics in its N-PORT filings yet. We sweep new filings monthly.